최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0099582 (2013-12-06) |
등록번호 | US-9012434 (2015-04-21) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 9 인용 특허 : 521 |
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estra
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
1. A method of treating menopause-related symptoms comprising administering once daily an effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising: about 50 mg progesterone;about 0.25 mg estradiol or about 0.26 mg estradiol hemihydrate;
1. A method of treating menopause-related symptoms comprising administering once daily an effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising: about 50 mg progesterone;about 0.25 mg estradiol or about 0.26 mg estradiol hemihydrate;about 98.24 mg of a solubilizing agent comprising monoglycerides and diglycerides containing esters of caprylic acid and capric acid (CAPMUL MCM); andabout 1.50 mg of at least one of lauroyl macrogol-32 glycerides EP, lauroyl polyoxyl-32 glycerides NF, or lauroyl polyoxylglycerides (GELUCIRE 44/14);wherein a portion of the progesterone is suspended;wherein the estradiol or estradiol hemihydrate is about 90% solubilized in the solubilizing agent; andwherein the estradiol or estradiol hemihydrate and suspended progesterone are uniformly dispersed. 2. The method of claim 1, wherein the pharmaceutical composition is administered as a continuous-combined therapy regimen. 3. The method of claim 1, wherein the pharmaceutical composition is administered as a sequentially-combined therapy regimen. 4. A method of treating the symptoms with menopause comprising administering an effective amount of a pharmaceutical composition comprising: 0.25 mg estradiol or about 0.26 mg estradiol hemihydrate, wherein the estradiol or estradiol hemihydrate is about 90% solubilized in the solubilizing agent;50 mg progesterone; anda solubilizing agent;wherein a portion of the progesterone is suspended;wherein the estradiol or estradiol hemihydrate and suspended progesterone are uniformly dispersed;wherein the solubilizing agent is selected from at least one of monoglycerides, diglycerides, triglycerides, and combinations thereof;wherein the monoglycerides, diglycerides, and triglycerides have an effective amount of C6-C12 fatty acid chain lengths; andwherein the pharmaceutical composition is administered once daily for the treatment of symptoms associated with menopause. 5. The method of claim 4, wherein the pharmaceutical composition is administered as a continuous-combined therapy regimen. 6. The method of claim 4, wherein the pharmaceutical composition is administered as a sequentially-combined therapy regimen. 7. The method of claim 4, wherein more than 50% of the monoglycerides, diglycerides, and triglycerides have C6-C12 fatty acid chain lengths. 8. A method of treating vasomotor symptoms in a woman comprising administering once daily an effective amount of a pharmaceutical composition comprising: a solubilizing agent;0.25 mg estradiol or about 0.26 mg estradiol hemihydrate, wherein the estradiol or estradiol hemihydrate is about 90% solubilized in the solubilizing agent; and50 mg progesterone;wherein the solubilizing agent comprises an effective amount of a C6-C12 oil;wherein a portion of the progesterone is suspended; andwherein the estradiol or estradiol hemihydrate and suspended progesterone are uniformly dispersed. 9. The method of claim 8, wherein the C6-C12 oil comprises C6-C12 monoglycerides and diglycerides. 10. The method of claim 9, wherein the monoglycerides and diglycerides contain esters of caprylic acid (C8) and capric acid (C10). 11. A method comprising administering once daily an effective amount of a pharmaceutical composition comprising: a solubilizing agent;0.25 mg estradiol or about 0.26 mg estradiol hemihydrate, wherein the estradiol or estradiol hemihydrate is about 90% solubilized in the solubilizing agent; and50 mg progesterone;wherein the solubilizing agent comprises an effective amount of a saturated C6-C12 oil;wherein a portion of the progesterone is suspended; andwherein the estradiol or estradiol hemihydrate and suspended progesterone are uniformly dispersed. 12. The method of claim 11, wherein the C6-C12 oil comprises a glyceride of at least one C6-C12 fatty acid. 13. The method of claim 11, wherein the C6-12 oil substantially contains esters of caprylic acid (C8) and capric acid (C10).
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.